Evidence map›Paper›PMID 30881616›Full record

ArticleMedChemComm2019

Design, synthesis and biological evaluation of novel 2-phenyl pyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.

Xinyu Li, Binyu Shi, Yu Teng, Yu Cheng, Huizhu Yang, Jiurong Li, Lianjian Wang, Siying He, Qidong You, Hua Xiang

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedChemComm, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. The Development of BTK Inhibitors: A Five-Year Update.Molecules (Basel, Switzerland) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Xinyu LiJiangsu Key Laboratory of Drug Design and Optimization , China Pharmaceutical University , Nanjing 210009 , China . Email: xianghua@cpu.edu.cn ; ; Tel: +86 025 83271096.
Binyu ShiJiangsu Key Laboratory of Drug Design and Optimization , China Pharmaceutical University , Nanjing 210009 , China . Email: xianghua@cpu.edu.cn ; ; Tel: +86 025 83271096.
Yu TengJiangsu Key Laboratory of Drug Design and Optimization , China Pharmaceutical University , Nanjing 210009 , China . Email: xianghua@cpu.edu.cn ; ; Tel: +86 025 83271096.
Yu ChengJiangsu Key Laboratory of Drug Design and Optimization , China Pharmaceutical University , Nanjing 210009 , China . Email: xianghua@cpu.edu.cn ; ; Tel: +86 025 83271096.
Huizhu YangJiangsu Key Laboratory of Drug Design and Optimization , China Pharmaceutical University , Nanjing 210009 , China . Email: xianghua@cpu.edu.cn ; ; Tel: +86 025 83271096.
Jiurong LiJiangsu Key Laboratory of Drug Design and Optimization , China Pharmaceutical University , Nanjing 210009 , China . Email: xianghua@cpu.edu.cn ; ; Tel: +86 025 83271096.
Lianjian WangJiangsu Key Laboratory of Drug Design and Optimization , China Pharmaceutical University , Nanjing 210009 , China . Email: xianghua@cpu.edu.cn ; ; Tel: +86 025 83271096.
Siying HeJiangsu Key Laboratory of Drug Design and Optimization , China Pharmaceutical University , Nanjing 210009 , China . Email: xianghua@cpu.edu.cn ; ; Tel: +86 025 83271096.
Qidong YouJiangsu Key Laboratory of Drug Design and Optimization , China Pharmaceutical University , Nanjing 210009 , China . Email: xianghua@cpu.edu.cn ; ; Tel: +86 025 83271096.
Hua XiangJiangsu Key Laboratory of Drug Design and Optimization , China Pharmaceutical University , Nanjing 210009 , China . Email: xianghua@cpu.edu.cn ; ; Tel: +86 025 83271096.ORCID 0000-0002-8937-4062
China Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BTK is an effective target for the treatment of B-cell malignant tumors and autoimmune diseases. In this work, a series of 2-phenyl pyrimidine derivatives were prepared and their preliminary

Identifiers

PMID30881616
PMCPMC6390688
OpenAlexW2910516558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.